Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck

Sponsor
Centre Leon Berard
Study ID
NCT03818061
Phase
PHASE2
Status
Completed

Conditions

  • Head and Neck Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — DRUG
    Patients will receive the combination of Atezolizumab 1200 mg and Bevacizumab 15 mg/kg by IV infusion every 3 weeks.
  • Bevacizumab — DRUG
    Patients will receive the combination of Atezolizumab 1200 mg and Bevacizumab 15 mg/kg by IV infusion every 3 weeks.

Study Details

This proof-of-concept study aims to assess the clinical and biological effects of Atezolizumab combined with Bevacizumab in advanced previously treated squamous-cell carcinoma of the head and neck (HNSCC).

Key Dates

Start date
Mar 26, 2019
Status verified
Apr 2026
Primary completion
Jan 15, 2025
Completion
Jan 15, 2025

Study Design

Enrollment
33 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: HPV +
    Patient with Human papillomavirus (HPV +) treated by Atezolizumab combined with Bevacizumab.
  • Experimental: HPV -
    Patient without Human papillomavirus (HPV - ) treated by Atezolizumab combined with Bevacizumab.

Primary Outcome Measure

Overall response rate [ Time Frame: At 18 weeks ]

Related Studies